XML 22 R10.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
SEGMENTS
3 Months Ended
Mar. 31, 2024
Segment Reporting [Abstract]  
SEGMENTS

4. SEGMENTS

 

Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision–making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision-maker is the CEO. The Company operates in and reports four business segments: real estate, digital transformation technology, biohealth, and other business activities. The Company’s reportable segments are determined based on the services they perform and the products they sell, not on the geographic area in which they operate. The Company’s chief operating decision maker evaluates segment performance based on segment revenue. Costs excluded from segment income (loss) before taxes and reported as “Other” consist of corporate general and administrative activities which are not allocable to the four reportable segments.

 

 

The following table summarizes the Company’s segment information for the following balance sheet dates presented, and for the three months ended March 31, 2024 and 2023:

 

   Real Estate   Digital Transformation Technology   Biohealth Business   Other   Total 
                     
Three Months Ended on March 31, 2024                         
Revenue  $5,752,994   $-   $535   $332,678   $6,086,207 
Cost of Sales   (4,533,660)   -    (2,041)   (122,666)   (4,658,367)
Gross Margin   1,219,334    -    (1,506)   210,012    1,427,840 
Operating Expenses   (361,696)   (163,707)   (826,961)   (2,341,990)   (3,694,354)
Operating Income (Loss)   857,638    (163,707)   (828,497)   (2,131,977)   (2,266,513)
Other Income (Expense)   15,148    (3,491,466)   (205,821)   1,365,140    (5,047,279)
Net Income (Loss) Before Income Tax   872,786    (3,655,173)   (1,034,288)   (3,497,117)   (7,313,792)

 

   Real Estate   Digital Transformation Technology   Biohealth Business   Other   Total 
                     
Three Months Ended on March 31, 2023                         
Revenue  $633,811   $14,040   $12,786   $266,299   $926,936 
Cost of Sales   (602,340)   (4,568)   (14,367)   (68,006)   (689,281)
Gross Margin   31,471    9,472    (1,581)   198,293    237,655 
Operating Expenses   (440,017)   (139,903)   (141,290)   (1,606,175)  $(2,327,385)
Operating Loss   (408,546)   (130,431)   (142,871)   (1,407,882)   (2,089,730)
Other Income (Expense)   45    (1,061,068)   319,635    (1,492,064)  $(2,233,452)
Net Loss Before Income Tax   (408,501)   (1,191,499)   176,764    (2,899,946)   (4,323,182)
                          
March 31, 2024                         
Cash and Restricted Cash  $2,988,864   $312,996   $411,751   $20,979,265   $24,692,876 
Total Assets   63,338,168    2,340,946    2,077,355    28,953,819    96,710,288 
                          
December 31, 2023                         
Cash and Restricted Cash  $3,323,210   $430,807   $568,702   $23,566,574   $27,889,293 
Total Assets   62,989,233    5,845,269    2,450,876    55,028,650    126,314,028